EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Obesity enhances the response to neoadjuvant anti‐ PD1 therapy in oral tongue squamous cell carcinoma

Xiyan Tan iD, Guoli Li, Honghao Deng, Guoming Xiao, Yaqin Wang, Chenzhi Zhang iD, Yanfeng Chen iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Xiyan Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Tongue Neoplasms, Neoadjuvant Therapy, Obesity, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Health Medical Collaborative Innovation Program of Guangzhou, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Previous studies have demonstrated that obesity may impact the efficacy of anti‐PD1 therapy, but the underlying mechanism remains unclear. In this study, our objective was to determine the prognostic value of obesity in patients with oral tongue squamous cell carcinoma (OTSCC) treated with pembrolizumab and establish a subtype based on fatty acid metabolism‐related genes (FAMRGs) for immunotherapy. Materials and Methods We enrolled a total of 56 patients with OTSCC who underwent neoadjuvant anti‐PD1 therapy. Univariate and multivariate Cox regression analyses, Kaplan–Meier survival analysis, and immunohistochemistry staining were performed. Additionally, we acquired the gene expression profiles of pan‐cancer samples and conducted GSEA and KEGG pathway analysis. Moreover, data from TCGA, MSigDB, UALCAN, GEPIA and TIMER were utilized to construct the FAMRGs subtype.

Results

Our findings indicate that high Body Mass Index (BMI) was significantly associated with improved PFS (HR = 0.015; 95% CI, 0.001 to 0.477; p = 0.015), potentially attributed to increased infiltration of PD1 + T cells. A total of 91 differentially expressed FAMRGs were identified between the response and non‐response groups in pan‐cancer patients treated with immunotherapy. Of these, 6 hub FAMRGs (ACSL5, PLA2G2D, PROCA1, IL4I1, UBE2L6 and PSME1) were found to affect PD‐1 expression and T cell infiltration in HNSCC, which may impact the efficacy of anti‐PD1 therapy.

Conclusion

This study demonstrates that obesity serves as a robust prognostic predictor for patients with OTSCC undergoing neoadjuvant anti‐PD1 therapy. Furthermore, the expression of 6 hub FAMRGs (ACSL5, PLA2G2D, PROCA1, IL4I1, UBE2L6 and PSME1) plays a pivotal role in the context of anti‐PD1 therapy and deserves further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tongue NeoplasmsNeoadjuvant TherapyObesityImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedPrognosisAgedSquamous Cell Carcinoma of Head and NeckAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorAdultBody Mass IndexBiomarkers, Tumor

Stichwörter der Autor:innen

fatty acid metabolismimmunotherapyobesityoral tongue squamous cell carcinomaprognosis

Substanzen

Immune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.

ORCID-Profile: Xiyan Tan, Chenzhi Zhang, Yanfeng Chen

Förderung

  • National Natural Science Foundation of China
  • Health Medical Collaborative Innovation Program of Guangzhou
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Tan, X., Li, G., Deng, H., Xiao, G., Wang, Y., Zhang, C., & Chen, Y. (2024). Obesity enhances the response to neoadjuvant anti‐ PD1 therapy in oral tongue squamous cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.7346

Vancouver

Tan X, Li G, Deng H, Xiao G, Wang Y, Zhang C, et al. Obesity enhances the response to neoadjuvant anti‐ PD1 therapy in oral tongue squamous cell carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.7346

BibTeX
@article{Tan2024,
  author = {Tan, Xiyan and Li, Guoli and Deng, Honghao and Xiao, Guoming and Wang, Yaqin and Zhang, Chenzhi and Chen, Yanfeng},
  title = {Obesity enhances the response to neoadjuvant anti‐ PD1 therapy in oral tongue squamous cell carcinoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7346}
}
Kostenlos starten →